Background
TAF
Edited by: Zhi-Feng Sheng, Central South University, ChinaReviewed by: Aoife Cotter, University College Dublin, Ireland; Anna Bonjoch, Hospital Germans Trias i Pujol, SpainThis article was submitted to Bone Research, a section of the journal Frontiers in EndocrinologyThe impact of tenofovir disoproxil fumarate (TDF) antiretroviral (ART) regimens on bone health has been characterized mostly by bone mineral density (BMD), but recently also by bone quality (BQ). The aim of this pilot study is to assess the changes in BMD and BQ after switch from TDF to tenofovir alafenamide (TAF) ART.